Key Insights

Highlights

Success Rate

85% trial completion

Published Results

16 trials with published results (25%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

7.9%

5 terminated out of 63 trials

Success Rate

85.3%

-1.2% vs benchmark

Late-Stage Pipeline

16%

10 trials in Phase 3/4

Results Transparency

55%

16 of 29 completed with results

Key Signals

16 with results85% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (5)
P 1 (9)
P 2 (15)
P 3 (8)
P 4 (2)

Trial Status

Completed29
Recruiting10
Unknown8
Terminated5
Withdrawn5
Not Yet Recruiting3

Trial Success Rate

85.3%

Benchmark: 86.5%

Based on 29 completed trials

Clinical Trials (63)

Showing 20 of 20 trials
NCT07159841Phase 2RecruitingPrimary

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

NCT07144163Phase 3RecruitingPrimary

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

NCT07536269Phase 2Not Yet RecruitingPrimary

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

NCT07187375Phase 2RecruitingPrimary

Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

NCT06728748CompletedPrimary

Retrospective Multicentre Study on the Impact of Neonatal Screening for Congenital Adrenal Hyperplasia in Italy

NCT05669950Phase 1RecruitingPrimary

A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

NCT05299554Phase 3CompletedPrimary

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

NCT06573723Recruiting

Institutional Registry of Rare Diseases

NCT05128942Phase 2TerminatedPrimary

A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH

NCT04783181Phase 1Active Not RecruitingPrimary

A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

NCT02795871Not ApplicableCompletedPrimary

Prenatal Dex Study

NCT05663320Not ApplicableWithdrawnPrimary

A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia

NCT02574910Phase 1TerminatedPrimary

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

NCT03257462Phase 2CompletedPrimary

Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia

NCT04544410Phase 2TerminatedPrimary

A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

NCT05907291Phase 2CompletedPrimary

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

NCT06712823Phase 2RecruitingPrimary

An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894

NCT03760835Phase 4RecruitingPrimary

Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment

NCT06756620Completed

Investigation of the Etiology of Hypertension and Endothelial Damage in Patients With Cytochrome P450 Oxidoreductase Deficiency

NCT05687474CompletedPrimary

Baby Detect : Genomic Newborn Screening

Scroll to load more

Research Network

Activity Timeline